Healthcare Sales & Marketing Network News: mesalamine

Searching News Database: mesalamine

HSMN NewsFeed - 2 Dec 2016
Allergan Announces Settlement of a DELZICOL(R) (mesalamine) Patent Litigation
Biopharmaceuticals Litigation

HSMN NewsFeed - 27 Sep 2016
Insmed Appoints Roger Adsett as Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Mar 2016
Shire Wins Patent Trial Against Watson Concerning LIALDA(R)
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 17 Jul 2014
Salix and Pharming Announce FDA Approval of RUCONEST(R) for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Feb 2013
Warner Chilcott Announces FDA Approval of New Ulcerative Colitis Product
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 2 Jan 2013
FDA Approves Fulyzaq(TM) (Crofelemer) 125 mg Delayed-Release Tablets for the Symptomatic Relief of Diarrhea in Patients with HIV/AIDS on Anti-Retroviral Therapy (ART)
Biopharmaceuticals FDA HIV/AIDS

HSMN NewsFeed - 30 Aug 2011
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR(R) in Patients with Non-Cancer Pain
Biopharmaceuticals FDA

HSMN NewsFeed - 8 Jul 2010
Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 8 Jun 2010
Salix Pharmaceuticals Announces NDA Submission For XIFAXAN550 For Treatment of Non-Constipation Irritable Bowel Syndrome
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 25 Mar 2010
Santarus Announces Completion of Enrollment in U.S. Phase III Clinical Study for Budesonide MMX
Biopharmaceuticals Drug Delivery Gastroenterology

HSMN NewsFeed - 24 Mar 2010
FDA Approves XIFAXAN(R) 550 MG Tablets for Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence
Biopharmaceuticals FDA

HSMN NewsFeed - 23 Feb 2010
FDA Advisory Committee Recommends Approval Of XIFAXAN(R) (rifaximin) Tablets, 550 Mg for Maintenance of Remission of Hepatic Encephalopathy
Biopharmaceuticals FDA

HSMN NewsFeed - 8 Sep 2009
Salix Receives FDA Marketing Approval for METOZOLV ODT (Orally Disintegrating Tablets) for Relief of Diabetic Gastroparesis and Symptomatic Documented GERD
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 24 Aug 2009
Warner Chilcott Acquires P&G's Global Pharmaceuticals Business
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 1 Jun 2009
Positive Results from Salix Pivotal Phase III Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE) Presented at Digestive Disease Week (DDW)
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 23 Apr 2009
Salix Presents Highly Statistically Significant Results from the Phase III Pivotal Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE)
Biopharmaceuticals

HSMN NewsFeed - 29 Dec 2008
Salix Receives FDA Complete Response Letter for Balsalazide Tablet
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 15 Dec 2008
COSMO ANNOUNCES STRATEGIC COLLABORATION WITH SANTARUS FOR U.S. RIGHTS TO BUDESONIDE MMX® AND RIFAMYCIN SV MMX®
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 3 Nov 2008
APRISO(TM) Granted FDA Marketing Approval for Maintenance of Remission of Ulcerative Colitis
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Oct 2008
Rifaximin Demonstrates Highly Statistically Significant Results in Prevention of Hepatic Encephalopathy in Pivotal Phase 3 Study
Biopharmaceuticals

HSMN NewsFeed - 26 Mar 2008
Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 6 Feb 2008
Salix Announces Appointment of Mark Sirgo to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Dec 2007
Salix Pharmaceuticals Announces Submission of Granulated Mesalamine New Drug Application
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 14 Dec 2007
Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
Biopharmaceuticals Licensing Gastroenterology

HSMN NewsFeed - 5 Dec 2007
Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 15 Oct 2007
New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 4 Oct 2007
Salix Announces Statistically Significant Top- Line Results for Second Product Registration Study of Granulated Mesalamine in Ulcerative Colitis
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 4 Oct 2007
Salix Pharmaceuticals Licenses OSMOPREP(TM) To Mayoly-Spindler in France
Biopharmaceuticals Licensing Gastroenterology

HSMN NewsFeed - 5 Sep 2007
Salix Pharmaceuticals Acquires Patent-Protected Metoclopramide-Zydis(R)
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 5 Sep 2007
Salix Pharmaceuticals Announces Co-Promotion Agreement for Balsalazide
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 5 Sep 2007
Rifaximin Demonstrates Statistically Significant Improvement in Co-Primary Endpoints in Treatment of Diarrhea-Associated Irritable Bowel Syndrome in Phase IIb Study
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 18 Jun 2007
Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 14 Jun 2007
Axcan Pharma Initiates MAX-002 Phase III Clinical Trial to Evaluate the Efficacy and Safety of a High-Concentration 1 Gram Mesalamine Suppository
Biopharmaceuticals

HSMN NewsFeed - 8 Jun 2007
Salix Pharmaceuticals Announces Imminent Launch of Visiclear(R) in Japan
Biopharmaceuticals

HSMN NewsFeed - 22 May 2007
Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of LIALDA(TM) (mesalamine) Presented at DDW
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 17 May 2007
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 19 Mar 2007
LIALDA(TM) (mesalamine) With MMX(TM) Technology - the First Oral Once-Daily Mesalamine for Active, Mild to Moderate Ulcerative Colitis - Now Available
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 28 Feb 2007
Salix Pharmaceuticals Acquires PEPCID(R) Oral Suspension
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 31 Jan 2007
Procter & Gamble Pharmaceuticals Commemorates 15 Years of Trusted Leadership With Asacol(R) (Mesalamine) Delayed-Release Tablets
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 16 Jan 2007
FDA Approves LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 11 Jan 2007
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
Biopharmaceuticals Regulatory

HSMN NewsFeed - 11 Jan 2007
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
Biopharmaceuticals Regulatory

HSMN NewsFeed - 22 Dec 2006
New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of ADHD
Biopharmaceuticals

HSMN NewsFeed - 20 Dec 2006
Colazal(R) Pediatric Indication Approved
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 13 Dec 2006
OSMOPREP(TM) Tablets Granted MHRA Marketing Approval
Biopharmaceuticals Regulatory

HSMN NewsFeed - 12 Dec 2006
Dr. Jeffrey Leiden Appointed Non Executive Director at Shire
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Dec 2006
Treatment of Ulcerative Colitis With Asacol Improved Patient Quality of Life in as Early as Three Weeks, According to New Data Analysis
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 17 Nov 2006
FOSRENOL(R) Data Show Evidence of Trends Towards Improved Bone Formation in CKD Stage 5 Patients, New Data Presented at ASN Meeting
Biopharmaceuticals

HSMN NewsFeed - 16 Nov 2006
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
Biopharmaceuticals

HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
Biopharmaceuticals

HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of a Meta-Analysis Comparing Stimulant Medications to Non-Stimulant Medications in Treating ADHD in Patients Aged 8 to 15
Biopharmaceuticals

HSMN NewsFeed - 10 Nov 2006
Shire Sues Andrx Pharmaceuticals, L.L.C.
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 26 Oct 2006
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
Biopharmaceuticals

HSMN NewsFeed - 23 Oct 2006
Salix Pharmaceuticals Reports American College of Gastroenterology Update
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 19 Oct 2006
ELAPRASE(TM) (idursulfase) Receives Positive Opinion in Europe
Biopharmaceuticals Regulatory

HSMN NewsFeed - 27 Sep 2006
Colazal(R) Food Effect Application Granted FDA Approval
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 8 Sep 2006
Shire Provides Update on U.S. Marketing Application of MESAVANCE(TM) (mesalamine) With MMX Technology
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 5 Jul 2006
COLAZAL(R) Pediatric Exclusivity Filing Submitted
Biopharmaceuticals Gastroenterology FDA

Return to NewsFeed

Additional items found! 30

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 30 additional stories matching:
mesalamine
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.